US Trauma Center signs commercial contract

Q-linea AB (publ) (OMX: QLINEA) announces adoption of the first Accelerate Pheno conversion to the ASTar system by a prominent US level 1 University Hospital Trauma Center.

The University hospital selected ASTar above other available rapid antibiotic susceptibility testing instruments for its full automation and inoculum control, high instrument throughput with random-access testing, as well as its broad antibiotic panel and wide dilution ranges. Following a successful evaluation period, the hospital’s clinical microbiology team has chosen to transition into routine clinical use of the system, is expected to start following implementation steps including LIS connectivity.

The team at Q-linea expect several more similar announcements in the months ahead.

Datum 2025-10-03, kl 10:00
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!